ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1018

Factors Associated with Mortality in Systemic Lupus Erythematosus under a Universal Healthcare System: Results from the CAPTURED Study, a Population-Based Cohort in Catalonia, Spain

José Gomez-Puerta1, Cristian Tebe2, Maria Grau3, Beatriz Frade Sosa4, Juan Camilo Sarmiento-Monroy5, Cristina Carbonell-Abella6, Daniel Martinez-Laguna7, Patricia Corzo8, Raimon Sanmartí9 and J. Antonio Aviña-Zubieta10, 1Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, 2Instituto de Investigación Germans Trias i Pujol, Badalona, Spain, 3University of Barcelona, Barcelona, Spain, 4Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, 5Hospital Clínic Barcelona, Barcelona, Spain, 6Medicina Familiar y Comunitaria, Centro de Salud Vía Roma, Barcelona, Spain, 7Grup de recerca en malalties prevalents de l'Aparell locomotor en Atenció Primaria (GREMPAL), ICS, Barcelona, Spain, 8Rheumatology Department, Hospital Clínic, Barcelona, Barcelona, Spain, 9Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, 10University of British Columbia/Arthritis Research Canada, Vancouver, BC, Canada

Meeting: ACR Convergence 2025

Keywords: Epidemiology, Mortality, population studies, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1007–1037) Epidemiology & Public Health Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: The differences in lupus-related mortality reported in population studies are partly explained by racial disparities and access to healthcare. However, population-based data from universal healthcare systems are less well known.Our objective was to determine factors related with mortality in SLE patients in Catalonia (Spain) during the period from January 1, 2006, and December 31, 2021.

Methods: We conducted a population-based cohort study (CAPTURED study, CatAlonia ePidemiology sTUdy in RhEumatic Diseases) of all existing Catalonian cases who received SLE diagnosis from 2006 to 2021 by using ICD-10-CM codes from the Information System for the Development of Primary Care Research (SIDIAP). A database of primary care electronic health records that includes data from 328 primary care practices covering 5.8 million people, 75% of the Catalan population.Patients with SLE were matched 1 with individuals from the Catalonia general population and estimate hazart ratio (HR) for mortality using a cox regression model adjusting by potential coufounding factors including sex, age, origin (Spanish vs non-Spanish), socioeconomic status (MEDEA*, Gotsens M et al. Accid Anal Prev. 2011 Sep;43(5):1802-10) and comorbidities (charlson score, CS).

Results: We identified 10,687 prevalent cases of SLE, with a mean age of 47.5 years (SD 16.3). Of these patients, 8,851 (83.4%) were female, and 6,885 (64.9%) had Spanish nationality. General characteristics are summarized in Table 1.During the study period, we identified 1,175 deaths among SLE cases (12.5%) and 11,499 (15.6%) among 824,028 controls. Age (HR 1.05, 95% CI 1.02–1.08), male sex (HR 1.60, 95% CI 1.58–1.63), and Charlson score (CS=1 HR 1.75, 95% CI 1.70–1.80; CS=2 HR 2.38, 95% CI 2.31–2.45; CS≥3 HR 3.50, 95% CI 3.38–3.62) were associated with increased mortality risk, while patients of Spanish origin had a lower risk of death (HR 0.94, 95% CI 0.90–0.98).After adjusting for confounding factors, patients with SLE had a slightly higher mortality rate compared to the general population (HR 1.09, 95% CI 1.01–1.17) (Figure 1).

Conclusion: In our population-based study conducted within a universal healthcare system, we observed a slight increase in mortality among patients with SLE. Socioeconomic status did not significantly impact mortality in these patients.

Supporting image 1Table 1. General characteristics of controls and SLE

Supporting image 2Adjusted HR for mortality in SLE in Catalonia (Spain)


Disclosures: J. Gomez-Puerta: AbbVie/Abbott, 6, AstraZeneca, 6, GlaxoSmithKlein(GSK), 6, Pfizer, 6; C. Tebe: None; M. Grau: None; B. Frade Sosa: Galapagos, 6, GlaxoSmithKlein(GSK), 6; J. Sarmiento-Monroy: AstraZeneca, 6, GlaxoSmithKlein(GSK), 6, Janssen, 6; C. Carbonell-Abella: None; D. Martinez-Laguna: None; P. Corzo: GlaxoSmithKlein(GSK), 6; R. Sanmartí: AbbVie/Abbott, 5, 6, Bristol-Myers Squibb(BMS), 5, 6, Eli Lilly, 5, 6, Merck/MSD, 5, 6, Pfizer, 5, 6, Roche, 5, 6; J. Aviña-Zubieta: None.

To cite this abstract in AMA style:

Gomez-Puerta J, Tebe C, Grau M, Frade Sosa B, Sarmiento-Monroy J, Carbonell-Abella C, Martinez-Laguna D, Corzo P, Sanmartí R, Aviña-Zubieta J. Factors Associated with Mortality in Systemic Lupus Erythematosus under a Universal Healthcare System: Results from the CAPTURED Study, a Population-Based Cohort in Catalonia, Spain [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/factors-associated-with-mortality-in-systemic-lupus-erythematosus-under-a-universal-healthcare-system-results-from-the-captured-study-a-population-based-cohort-in-catalonia-spain/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/factors-associated-with-mortality-in-systemic-lupus-erythematosus-under-a-universal-healthcare-system-results-from-the-captured-study-a-population-based-cohort-in-catalonia-spain/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology